The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Trading partnership - it involves large gross figures [ being aa global player they won't be buying a couple of tons!] and there's a market price - the local knowledge of the region and the players [ who will be known to our Morrocan CEO - as he founded the Morrocan Miners Association] means renumeration could be based on notional % savings [v attractive] or a straight % [attractive]]
It's all educated guesswork at this stage but V mcap of £700k the RvR looks excellent
If the partnership delivers even modestly, it would put CMRS as the only junior generating cash = no placing needed - the major problem for all juniors [and the small cap market generally] cash.
Only 70m shares. Just tuck a few away
Amati sold, it's not because of redemptions. That's because the shares are not held in the open-ended fund but in the permanent capital VCT compliant AIM investment trust, AMAT.
Re: the strategic review announced by AMAT last month it's a good thing in my opinion. That's because the trust has to operate under v onerous restrictions in order to preserve VCT status. For instance, they cannot buy shares in the open market. Purchases can only be made at an IPO or at a subsequent placing, which means they cannot buy more of a share simply because the price has fallen and they reckon it's good value. Similarly, they cannot buy a share they have previously sold. Imagine investing in that way - it's hard enough making money on AIM, without having to navigate these VCT compliant handicaps additionally. I'm therefore not in the least surprised that AMAT has been such a poor performer ; this financial instrument gives rise to a sparkling unique opportunity to get in after all the hard work (£) has been done but they can’t buy back.
Excellent summary of the massive and very realistic potential and thank the Lord, a post about the company and cos and not bickering / name calling. As you say, invest in the company not the hourly price.